Now showing items 1-1 of 1

    • Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. 

      Dominique, Germain.; Derralynn, Hughes.; Kathleen, Nicholls.; Daniel, Bichet.; Giugliani, Roberto.; Wilcox, William.; Amartino, Hernán.; et al. (Massachusetts Medical Society, 2016-08-11)
      BACKGROUND: Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency, leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms ...